Altimmune (ALT) said Tuesday it entered into an agreement with Hercules Capital (HTGC) for a credit facility of up to $100 million, with $15 million funded at closing.
The company said additional funding will be tied to the achievement clinical and financial milestones for pemvidutide, its GLP-1 agonist.
Pemvidutide is currently being evaluated in a mid-stage study for metabolic dysfunction-associated steatohepatitis, with results expected in Q2 and additional phase 2 trials in alcohol use disorder and alcohol liver disease planned for later this year.
Altimmune said the new facility will strengthen its balance sheet, which included $150 million in cash and cash equivalents as of March 31.
Shares of Altimmune rose 1.5% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.